Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
The primary objective of this study was to evaluate the effect of eleclazine (GS-6615) on
 exercise capacity as measured by Peak oxygen uptake (VO2) achieved during cardiopulmonary
 exercise testing (CPET), in participants with symptomatic hypertrophic cardiomyopathy (HCM).
Key Inclusion Criteria:

 -  Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a
 maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis

 -  Exertional symptoms including at least one of the following:

 -  New York Heart Association (NYHA) Class ≥ II dyspnea

 -  Canadian Cardiovascular Society (CCS) Class ≥ II angina

 -  Screening (baseline) peak VO2 < 80% of predicted for age, sex, and weight

 -  Ability to perform an upright treadmill cardiopulmonary exercise test (CPET)

 Key Exclusion Criteria:

 -  Known aortic valve stenosis (moderate or severe)

 -  Known coronary artery disease

 -  Left ventricular systolic dysfunction (ejection fraction < 50%)

 -  Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation)
 within six months prior to screening or such a procedure scheduled to occur during the
 study

 Note: Other protocol defined Inclusion/Exclusion criteria may apply.